 |
Video: What is a Stock Split?
|
 |
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L. According to our Cti Biopharma stock split history records, Cti Biopharma has had 2 splits. | |
 |

Cti Biopharma (CTIC) has 2 splits in our Cti Biopharma stock split history database. The first split for CTIC took place on September 04, 2012. This was a 1 for 5 reverse split, meaning for each 5 shares of CTIC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split. CTIC's second split took place on January 03, 2017. This was a 1 for 10 reverse split, meaning for each 10 shares of CTIC owned pre-split, the shareholder now owned 1 share. For example, a 200 share position pre-split, became a 20 share position following the split.
When a company such as Cti Biopharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Cti Biopharma stock split history from start to finish, an original position size of 1000 shares would have turned into 20 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cti Biopharma shares, starting with a $10,000 purchase of CTIC, presented on a split-history-adjusted basis factoring in the complete Cti Biopharma stock split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/26/2013 |
|
End date: |
06/26/2023 |
|
Start price/share: |
$16.00 |
|
End price/share: |
$9.09 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-43.19% |
|
Average Annual Total Return: |
-5.63% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,682.57 |
|
Years: |
9.75 |
|
|
 |
Date |
Ratio |
09/04/2012 | 1 for 5 | 01/03/2017 | 1 for 10 |
|
 |